Abstract
Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bhatavdekar, J., Patel, D., Giri, D. et al. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Br J Cancer 66, 977–980 (1992). https://doi.org/10.1038/bjc.1992.395
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.395
This article is cited by
-
A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers
Clinical Proteomics (2015)
-
Role of Prolactin and Its Receptor in Colorectal Cancer
Current Colorectal Cancer Reports (2014)
-
Plasma prolactin in patients with colorectal cancer
BMC Cancer (2004)
-
Ectopic production of prolactin by colorectal adenocarcinoma
Diseases of the Colon & Rectum (2001)
-
Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma
Diseases of the Colon & Rectum (2001)